TROP-2, also known as trophoblast cell-surface antigen 2, is a membrane-bound cancer antigen and trop 2.2 target that functions primarily as an antibody drug conjugates and imaging/therapy target. It is associated with cancer invasiveness and poorer patient outcomes, and in non-small cell lung cancer (NSCLC) it is being profiled as an ADC target while generalizable AI can separate TROP-2 phenotypes. The antigen is also used in radioimmunotherapy, including Trop-2.2-directed approaches, and in immunopet to select patients with Trop-2-positive lesions. Recent studies extend its therapeutic relevance beyond NSCLC to pancreatic cancer models, where Trop-2.2-directed radioimmunotherapy was evaluated with 177Lu, 225Ac, and 212Pb. Overall, TROP-2 is a clinically actionable surface marker with roles in patient selection, targeted delivery, and radionuclide therapy.
Cancer
- TROP-2 is a membrane-bound antigen associated with cancer invasiveness and poorer patient outcomes, supporting its use as a therapeutic target. (PMID:41591978)
- In NSCLC, ADCs targeting TROP-2 are entering clinical trials, highlighting its role in antibody drug conjugates development. (PMID:41945491)
- Generalizable AI was reported to separate TROP-2 phenotypes in NSCLC, suggesting a new way to stratify target expression for therapy selection. (PMID:41945491)
- Trop-2.2-directed radioimmunotherapy was tested in a pancreatic cancer model using 177Lu, 225Ac, and 212Pb. (PMID:41591978)
Imaging and Patient Selection
- Trop-2.2 immunoPET was established to select patients with Trop-2-positive lesions, linking immunopet to target-based patient stratification. (PMID:41591978)
- Trop-2.2 serves as the targeting antibody against TROP-2 for imaging and therapy selection. (PMID:41591978)
- The NSCLC profiling study indicates that AI-based phenotype separation may improve identification of TROP-2-expressing tumors. (PMID:41945491)